Tag: press release

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose Investments”) announced today its decision to terminate StoneCastle Equity Growth Fund and StoneCastle Income Growth Fund (each, a “StoneCastle Fund” and together, the “StoneCastle Funds”) at the close of business on or about September 29, 2025 (the “StoneCastle Funds’ Termination Date”). Effective immediately, each StoneCastle Fund is closed to new purchases. Purpose Investments also announced its decision to terminate PK Core Fund effective as of the close of business today. PK Core Fund currently has no unitholders and is closed to new purchases.

New York, July 25, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") for its client Garden Stage Limited (NASDAQ: GSIW) (“GSIW” or the “Company”), a Hong Kong-based financial services provider.

CORYDON, Ind., July 25, 2025 (GLOBE NEWSWIRE) -- First Capital, Inc. (the “Company”) (NASDAQ: FCAP), the holding company for First Harrison Bank (the “Bank”), today reported net income of $3.8 million, or $1.13 per diluted share, for the quarter ended June 30, 2025, compared to net income of $2.8 million, or $0.85 per diluted share, for the quarter ended June 30, 2024.

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 408.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.